期刊文献+

健康女性血清HE4和CA125水平及ROMA值的调查 被引量:13

Serum HE4 CA125 and ROMA level in healthy women of China
下载PDF
导出
摘要 目的评估健康女性血清HE4,CA125水平及ROMA值,建立相应的95%可信区间。方法利用电化学发光免疫测定法检测健康女性血清HE4和CA125的水平,计算HE4/CA125、ROMA值以及HE4、CA125、HE4/CA125和ROMA的95%可信区间,同时分析其在不同年龄组、不同绝经状态下的分布规律。结果健康女性血清HE4和CA125及HE4/CA125和RO-MA的95%可信区间分别为HE4≤82.62pmol/L,CA125≤30.91U/mL,HE4/CA125≤6.49,ROMA≤19.27。健康女性血清HE4水平在60岁以上年龄组高于其他年龄组;50岁以上的健康女性血清CA125水平明显低于50岁及以下的健康女性;而HE4/CA125在50岁以上的健康女性中明显高于50岁以下的;健康女性>50~60岁年龄段的ROMA值低于60岁以上年龄段,而明显高于50岁以下年龄段(P<0.05)。绝经后健康女性血清HE4水平以及HE4/CA125、ROMA值高于绝经前健康女性,而CA125的水平绝经后低于绝经前(P<0.05)。HE4/CA125与ROMA在绝经前健康女性组成正相关,而在绝经后组成负相关。结论本研究可为评估中国健康女性HE4、CA125、ROMA水平及建立相应的参考区间提供一个参考。 Objective To assess the HE4,CA125,ROMA level and establish the corresponding 95% confidence intervals in healthy Chinese women.Methods HE4 and CA125 serum concentrations were determined in a group of healthy women in China with electrochemiluminescence immunoassay(ECLIA).Then calculated the value of HE4/CA125,ROMA and the 95% confidence intervals(CI) of HE4,CA125,HE4/CA125 and ROMA,and analyzed its distribution in different age groups and different menopausal status.Results The 95%CI were HE4≤82.62 pmol/L,CA125≤30.91 U/mL,HE4/CA125≤6.49 and ROMA≤19.27.The concentration of HE4 in &gt;60 years-old women was higher than women in other age.The concentration of CA125 in &gt;50 years old women was lower in ≤50 years-old women.The HE4/CA125 in &gt;50 years old women was higher in ≤50 years-old women.The ROMA value in &gt;60 years-old women was higher than that of &gt;50-60 years old.Women ≤50 years-old had a lower ROMA value than &gt;50-60 years-old(P&lt;0.05).The concentration of HE4 and HE4/CA125,ROMA in postmenopausal group was higher than premenopausal group(P&lt;0.05).The CA125 concentration in postmenopausal group was lower than premenopausal group(P&lt;0.05).Conclusion The results could provide a reference to assess the HE4,CA125,ROMA level and establish the corresponding reference intervals in healthy Chinese women with electrochemiluminescence immunoassay(ECLIA).
出处 《国际检验医学杂志》 CAS 2013年第16期2129-2130,2132,共3页 International Journal of Laboratory Medicine
关键词 人附睾蛋白4 CA-125抗原 ROMA 电化学发光法 卵巢癌 Human Epididymis Protein 4 CA-125 antigen Risk of Ovarian Malignancy Algorithm electrochemiluminescence immunoassay ovarian cancer
  • 相关文献

参考文献15

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [J] CA Cancer J C1in,2008,62(1) :10 29.
  • 2Jaeobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian Cancer[J]. Mol Cell Proteomics, 2004,3 (4) : 355 366.
  • 3蔡徐山,朱晴晖.一个有希望的卵巢癌新标志物——人附睾上皮分泌蛋白4[J].检验医学,2011,26(12):876-882. 被引量:4
  • 4Sandri MT, Bottari F, Franchi D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: corre lation with pathological outcome[J]. Gynecol Oncol 2013, 128 (2):233 238.
  • 5Dunleavey R. Importance o{ early diagnosis in managing ovarian Cancer[J]. Nurs Times, 2006,102 (41) : 28-29.
  • 6Chan KK,Chen CA,Nam JH,et al. The use of I-tE4 in "the predic- tion of ovarian Cancer in Asian women with a pelvic mass[J]. Gy- necol Oncol,2013,128(2) :239-244.
  • 7Valentin L. Use of morphology to characterize and manage com- mon adnexat masses[J]. Best Pratt Res Clin Obstet Gynaeeol, 2004 ,Ig(1) :71-89.
  • 8Clauss A,Lilia H,Lundwall A. A locus on human chromosome 20 con tains several genes expressing protease inhibitor domains with homology to whey acidic protein[J]. Biochem J,2002,368(Pt 1):233 242.
  • 9Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial Cancer management[J]. Expert Rev Mol Diagn, 2009,9(6) :555 566.
  • 10Moore RG, Mcmeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of o varian Cancer in patients with a pelvic mass[J]. Gynecol Oneol, 2009,112(1) :40 46.

二级参考文献42

  • 1Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004 [J]. CA Cancer J Clin, 2004, 54 ( 1 ) :8-29.
  • 2Posadas EM, Davidson B, Kohn EC, et al. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature [J]. Curr Opin Oncol, 2004, 16(5) :478-484.
  • 3Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer [J]. Gynecol Oncol, 2005, 99(2) :267-277.
  • 4Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis [J]. Clin Cancer Res, 2004, 10(10) :3291- 3300.
  • 5Van der Merwe DE, Oikonomopoulou K, Marshall J et al. Mass spectrometry: uncovering the cancer proteome for diagnostics [ J ]. Adv Cancer Res, 2007, 96:23-50.
  • 6Bast RC Jr, Klug TL, St John E, et al. A radioim-munoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer [ J ]. N Engl J Med, 1983, 309(15) : 883-887.
  • 7Brazert J, Pietryga M, Szablonski W, et al. Diagnostic value of the morphological ultrasound score system and the serum concentration of CA125 in the diagnosis of malignant ovarian cancer [ J ]. Ginekol Pol, 2003, 74(12) :1542-1548.
  • 8Komai K, Nishida T. Tumor marker in ovarian cancer [J]. Gan To Kagaku Ryoho, 2002, 29 (3) : 481- 486.
  • 9Di Cocco B, Calabretta F, Alghisi F, et al. Tumor markers in epithelial ovarian cancer [ J ]. Minerva Ginecol, 2003, 55(4): 327-332.
  • 10Kirchhoff C, Habben I, Ivell R, et al, A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors [ J ]. Biol Reprod, 1991,45 (2) :350-357.

共引文献3

同被引文献95

  • 1丁永慧,张治宁.CA125和CA199检测对卵巢上皮癌的诊断价值[J].宁夏医学院学报,2005,27(6):454-456. 被引量:9
  • 2沈剑虹,陆品相.血清CA199检测对消化道恶性肿瘤的临床意义[J].中国现代医学杂志,2008,18(20):3056-3057. 被引量:15
  • 3张银萍,罗银玲,王生龙,刘波,王馥瑜.8572名职工体检者血液生化分析[J].宁夏医科大学学报,2012,34(4):389-391. 被引量:1
  • 4周位强,沈琪琳,张继惠.更年期女性部分生化指标的变化及意义[J].广东医学,2007,28(6):944-945. 被引量:7
  • 5Bouchard D,Morisset D,Bourbonnais Y,et al.Proteins with whey-acidic-protein motifs and cancer[J].Lancet Oncol,2006,7(2):167-174.
  • 6Galgano MT,Hampton GM,Frierson HF.Comprehensive analysis of HE4 expression in normal and malignant human tissues[J].Mod Pathol,2006,19(6):847-853.
  • 7Kurdoglu Z,Gursoy R,Kurdoglu M,et al.Comparison of the clni- cal value of CA125 for the diagnosis of endometriosis[J],Fertil Steril,2009,92(15):1761-1763.
  • 8Diamandis E P, Hoffman B R, Sturgeon CM,et al. NationalAcademy of Clinical Biochemistry Laboratory Medicine PracticeGuidelines for the Use of Tumor Markers. Clinical Chemistry,2008,54(11): 1935-1939.
  • 9Park Y,Kim Y,Lee EY,et al. Reference ranges for HE4 and CA125 in a large Asian population by automated as- says and diagnostic performances for ovarian cancer[J]. Int J Cancer,2012,130(5) :1136-1144.
  • 10Kristjansdottir B, Levan K, Partheen K, et al. Diagnostic performanceof the biomarkers HE4 and CA125 in type I and type II epithelial ovariancancei[J]. Gynecol Oncol, 2013, 131 (1) : 52-58.

引证文献13

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部